Last reviewed · How we verify
Torasemide Prolonged Release
At a glance
| Generic name | Torasemide Prolonged Release |
|---|---|
| Also known as | Torasemide Prolonged release:Sutril neo |
| Sponsor | Ferrer Internacional S.A. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure (PHASE4)
- Hypertension Study: Multinational Torasemide Trial in Mild to Moderate Hypertension. (PHASE4)
- Investigator Initiated Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics. (PHASE4)
- Single Dose Study to Compare the Pharmacodynamics of Torasemide-PR 10 mg,Torasemide-IR 10 mg and Furosemide-IR 40 mg in Patients With Compensated Heart Failure (PHASE4)
- Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Torasemide Prolonged Release CI brief — competitive landscape report
- Torasemide Prolonged Release updates RSS · CI watch RSS
- Ferrer Internacional S.A. portfolio CI